TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01935180

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy Cap
Description: 4mm transparent cap (Olympus) mounted to the tip of a colonoscope.
Study: NCT06004947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Administered orally.
Study: NCT04281550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Think Drink
Description: The Think Drink Guide that had three interacting components. The 'policy' component was directed at the governance of the care home, whereas 'practice' components were directed at hydration procedures and processes, and 'educational' components that provided learning resources for care home staff to develop knowledge and understanding of hydration care. Think Drink was implemented through a short awareness-raising educational programme and accompanying information booklet detailing a range of practices (including organisational, system and individual practice) designed to encourage hydration.
Study: NCT03475615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130mg/m2, d1, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2, d1, q3w
Study: NCT01379781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention for PPD
Description: We will select a sample of pregnant women at risk for PPD, teach parenting skills to increase infant nocturnal sleep and reduce fuss/cry behavior to half of the sample during 3 perinatal visits.
Study: NCT02546388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium-68 DOTATATE
Study: NCT02951000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platysma suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no platysma suture
Study: NCT03863080

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RVT-1401
Description: Subcutaneous administration of RVT-1401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1401
Description: Subcutaneous administration of RVT-1401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1401
Description: Subcutaneous administration of RVT-1401

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration of Placebo
Study: NCT03054246

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of chewing side preference
Description: The visual analog scale (VAS) is used. The individual will be asked to make 1 mark on a 10-cm line with  always left and always right at either end and with  no preference in the middle.
Study: NCT01080079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride
Description: 4% w/w Terbinafine Hydrochloride Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride
Description: 4% w/w Terbinafine Hydrochloride Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride
Description: 4% w/w Terbinafine Hydrochloride Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride
Description: 4% w/w Terbinafine Hydrochloride Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride
Description: 4% w/w Terbinafine Hydrochloride Gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Purified Water
Description: Purified Water
Study: NCT01355952

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid
Description: 600mg three times per day (1800mg total) daily for 10 weeks
Study: NCT03656289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel 68Mg Implant
Description: Participants will have an etonogestral contraceptive implant (NEXPLANON) placed sub-dermally just under the skin at the inner side of the non-dominant upper arm.
Study: NCT00119184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External cephalic version
Description: 7.5 mg bupivacaine intrathecally

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External cephalic version
Description: 7.5 mg bupivacaine intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: spinal anesthesia
Study: NCT01580163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JITAI Combined with psychological intervention
Description: tablet，Each tablet weight 0.4g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Oral Solution，1mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine JITAI
Description: tablet，Each tablet weight 0.4g
Study: NCT00921375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TULY
Description: TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
Study: NCT04881994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.
Study: NCT03095859

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical rehabilitation.
Description: Early mobility, aerobic exercise, upper and lower limb strength and flexibility training, trunk mobility and core strengthening, inclusive of respiratory therapy and education.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation.
Description: Early mobility, aerobic exercise, upper and lower limb strength and flexibility training, trunk mobility and core strengthening, inclusive of respiratory therapy and education.
Study: NCT00525161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first.
Study: NCT00710697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picoplatin
Description: IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT01213680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monofer (iron isomaltoside 1000)
Description: 1000 mg iron isomaltoside administered as a infusion over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monofer
Description: 500 mg iron isomaltoside 1000 given as bolus injection over 2 minutes
Study: NCT02917096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03475615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 40mg/m2 ip，d1、8 ,q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)
Description: 40mg/m2 Bid po，d1-14,q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)
Description: 40mg/m2 Bid po，d1-14,q3w
Study: NCT06195254

Intervention type: RADIATION
Intervention: Stereotactic body radiotherapy (SBRT)
Description: All the patients first received SBRT with the dose of 25Gy up to 50Gy in five fractions.

Intervention type: DRUG
Intervention: PD-1 blocking antibody
Description: All the patients first received SBRT with the dose of 25Gy up to 50Gy in five fractions and then received the treatment of PD-1 blockers including pembrolizumab (200 mg every 3 weeks), carelizumab (200 mg every 3 weeks), tislelizumab (200 mg every 3 weeks), sintilimab (200 mg every 3 weeks), zimberelimab (240 mg every 3 weeks) until the tumor progressed or the side effects became intolerable.
Study: NCT04581668

Intervention type: OTHER
Group type: OTHER
Intervention: Neurally adjusted ventilatory assist first
Description: Invasive ventilation in Neurally adjusted ventilatory assist during 60 minutes followed by a 30 minutes wash out period then ventilation in conventional mode

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional ventilation first
Description: Invasive ventilation in conventional mode during 60 minutes followed by a 30 minutes wash out period then ventilation in Neurally adjusted ventilatory assist
Study: NCT00624143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORAL VORICONAZOLE and IV Amphotericin B
Description: Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC \>1000/MM3 or development of fungal infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORAL VORICONAZOLE and IV Amphotericin B
Description: Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC \>1000/MM3 or development of fungal infection
Study: NCT05342909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5x a week BFR training group
Description: This group will perform the two exercises 5x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2x a week BFR training group
Description: This group will perform the two exercises 2x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.
Study: NCT01990560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period
Study: NCT01236339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
Description: TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LVP
Description: Large Volume Paracentesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol
Study: NCT02054741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Complete geriatric assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03390374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin Oral
Description: Nystatin oral suspension
Study: NCT04196101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Four tablets daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four tablets daily for 5 days
Study: NCT00784693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: 15 mg IV single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV single dose
Study: NCT04621591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saneso 360° gastroscope
Description: Subjects will have a clinically indicated per standard of care routine EGD procedure performed with the Saneso 360° gastroscope.
Study: NCT01501760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Three subconjunctival injections of 0.5 ml of bevacizumab at: inclusion, 1 month, 2 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: Three subconjunctival injections 0.5 ml placebo (Balanced salt) solution at inclusion, 1 month, 2month
Study: NCT01362257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Period 1 - IV dose of GSK573719
Description: single dose of 65µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Period 2 - Oral dose of GSK573719
Description: single dose of 1000µg
Study: NCT03656523

Intervention type: OTHER
Intervention: Acute coronary syndrome and PCI and AF
Description: Patient with ACS and ACS treated with PCI
Study: NCT03154060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott FreeStyle Libre Flash Glucose Monitoring sensors
Description: Three FGM sensors will be inserted simultaneously (one on the back of the upper arm, abdomen and thigh) and will be worn for a consecutive 14 days. Throughout the study, patients should measure capillary blood glucose (BG) with the built-in BG meter of the Freestyle Libre at least 7 times per day (before and 1-2 hours after every meal and before bedtime). Additionally, patients should scan each sensor at least every 8 hours to obtain every measured interstitial glucose value. At the end visit (after 14 days), patients will come back to the hospital to download FGM and SMBG data.
Study: NCT00220753

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IQAir Allergen 100 Air cleaners
Description: Two air cleaners are installed in the patient's room, one in his bedroom, and one in the living room. The cleaners can be run at 5 different speeds: Speed 1 filtrates 60m3 of air per hour, speed 2 filtrates 90 m3 per hour, speed 3 filtrates 130 m3 per hour, speed 4 filtrates 240 m3 per hour, and speed 5 filtrates 380 m3 per hour. A timer-on period can be pre-set for every day of the week, but the cleaner can be run even in the timer-off period, at a speed pre-set and different from the timer-on period. Different timer-on off periods cannot be selected for different days, but the different days of the week can be pre-set to apply timer-on periods or not.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IQAir Allergen 100 Air cleaners
Description: Two air cleaners are installed in the patient's room, one in his bedroom, and one in the living room. The cleaners can be run at 5 different speeds: Speed 1 filtrates 60m3 of air per hour, speed 2 filtrates 90 m3 per hour, speed 3 filtrates 130 m3 per hour, speed 4 filtrates 240 m3 per hour, and speed 5 filtrates 380 m3 per hour. A timer-on period can be pre-set for every day of the week, but the cleaner can be run even in the timer-off period, at a speed pre-set and different from the timer-on period. Different timer-on off periods cannot be selected for different days, but the different days of the week can be pre-set to apply timer-on periods or not.
Study: NCT01994668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: A single intravenous administration of 2 mg lorazepam over 1 minute

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single intravenous administration of 0.9% saline over 1 minute
Study: NCT02080741

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample of 12 ml

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample of 12 ml
Study: NCT02917096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study: NCT00750438

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Propionate ester
Description: The subject will take propionate ester at the dose specified by the dose finding study, three times a day for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inulin
Description: The subjects in this group will take inulin at a comparable dose, three times a day for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: The subjects in this group will take the non fermentable carbohydrate, cellulose, at a comparable dose for 24 weeks.
Study: NCT03213691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO
Study: NCT00928408

Intervention type: DRUG
Intervention: Cinacalcet
Study: NCT06409546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocopherol and pentoxifilline topical gel
Description: Oral gel applied locally on the MRONJ related lesions or post-extraction sockets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral gel applied locally on the MRONJ related lesions or post-extraction sockets
Study: NCT04016623

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1-day toric test contact lens
Description: somofilcon A 1-day toric test contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-day toric test contact lens
Description: somofilcon A 1-day toric test contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1-day toric control contact lens
Description: somofilcon A 1-day toric control contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-day toric control contact lens
Description: somofilcon A 1-day toric control contact lens
Study: NCT00174187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day
Study: NCT01703767

Intervention type: BEHAVIORAL
Intervention: Provider Education Workshop
Description: Educational resources for physicians regarding the needs of GW1V patients.
Study: NCT04633265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG-I Mapping of Atrial Fibrillation
Description: Catheter ablation of Atrial Fibrillation guided by ECG-I
Study: NCT04235608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled sedation with sevoflurane
Description: Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous sedation with propofol
Description: intravenous sedation with propofol, as already routinely used in participating ICUs.
Study: NCT01063751

Intervention type: DEVICE
Group type: OTHER
Intervention: Tritanium® Primary Acetabular Shell
Description: Tritanium® Primary Acetabular Shell in total hip replacement.
Study: NCT04489173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trifluridine/tipiracil
Description: Study medication should be started within 3 days after completion of screening and continue until a study treatment discontinuation criterion is met.~Trifluridine/tipiracil will be administered orally BID on days 1 through 5, with the first dose administered in the morning of day 1 of each cycle and the last dose administered in the evening of day 5, followed by a recovery period from day 6 through day 7. Trifluridine/tipiracil will be administered orally BID on days 8 through 12, with the first dose administered in the morning of day 8 of each cycle and the last dose administered in the evening of day 12, followed by a recovery period from day 13 through day 28. Each cycle will be 28 days.
Study: NCT02283853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon β-1a
Description: administered by intramuscular injection
Study: NCT03173248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: Tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered SC or IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Administered SC or IV
Study: NCT02828826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone coaching
Study: NCT04003246

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic RT and Durvalumab
Description: 1500mg every 4 weeks \[Q4W\] intravenous \[IV\], first dose within 3 days of RT initiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidative Durvalumab
Description: 1500mg every 4 weeks \[Q4W\] intravenous \[IV\] up to one year
Study: NCT04077099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5093
Description: Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.
Study: NCT02023463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: Given IM or SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Undergo image-guided radiation therapy
Study: NCT01821690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone/placebo will be given in increasing increments of 15 mg as needed. Subjects will start with 15 mg on day one and end with 60 mg on day 91 or placebo equivalent. Dose is titrated based on treatment response.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablets taste and look identical to buspirone.